熱門資訊> 正文
4D分子治疗法布里候选人临床搁置解除
2024-08-10 02:46
- The U.S. FDA has lifted a clinical hold on a phase 1/2 study of 4D Molecular Therapeutics' (NASDAQ:FDMT) 4D-310, its candidate for Fabry disease cardiomyopathy.
- The hold was disclosed in February 2023 after the company had three reports of atypical hemolytic uremic syndrome in trials.
- 4D Molecular said enrollment in the study will resume in this half of the year.
- The company ended Q2 (June 30) with $578M in cash and cash equivalents, enough, it said, to fund operations through H1 2027.
More on 4D Molecular Therapeutics
- 4D Molecular Therapeutics: Yesterday's Wet-AMD Data Given Thumbs Down By Market
- 4D Molecular Therapeutics: R100 Vector Pushes Forward To Bring Q4 Of 2024 DME Data
- 4D Molecular Therapeutics, Inc. (FDMT) Special Call Transcript
- 4D Molecular Therapeutics GAAP EPS of -$0.63 beats by $0.06, revenue of $0.01M misses by $0.68M
- 4D Molecular Therapeutics falls 30% following phase 2 wet AMD candidate data
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
